Kazia Therapeutics (NASDAQ:KZIA) shares are trading higher on Wednesday after the company confirmed at the SNO it's Paxalisib data had positive safety and efficacy signals in Glioblastoma.
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer.
Kazia Therapeutics shares were trading up 49.95% at $14.82 at last check Wednesday. The stock has a 52-week range between $15.15 and $2.47.